Clinical trials: Coronavirus Disease-2019
Coronavirus Disease 2019
Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura
At the end of January 2020, the international community was informed of the presence of a new viral disease that started in Wuhan (China) and spread rapidly throughout the world.
- Trial name
- COVIXTREM (NCT04724850)
- Where
- Spain
- Volunteers
- 440 people
- Sponsor
- Juan Fernando Masa Jiménez
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with…
- Trial name
- NCT04501952
- Testing
- RDV
- Where
- 104 sites in United States, Denmark and 2 more
- Volunteers
- 584 people
- Sponsor
- Gilead Sciences
COVID-19, Cystic Fibrosis
COVID-19 Antibody Responses in Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT05614336)
- Testing
- Blood sample
- Where
- 19 sites in France
- Volunteers
- 331 people
- Sponsor
- Hospices Civils de Lyon
COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
- Trial name
- RESOLUTION (NCT04417257)
- Testing
- LAU-7b
- Where
- 29 sites in United States, Canada
- Volunteers
- 351 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Coronavirus Disease 2019
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04672564
- Testing
- Carrimycin
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 93 people
- Sponsor
- Shenyang Tonglian Group CO., Ltd
SARS-CoV-2, Coronavirus Infection
Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in…
- Conditions
- SARS-CoV-2, Coronavirus Infection, Asymptomatic Condition, COVID-19
- Trial name
- PEACE (NCT04346667)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 3 sites in Pakistan
- Volunteers
- 125 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
Healthy Participants
Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
The purpose of this study is to estimate the effect PF-07321332/Ritonavir and Ritonavir on Midazolam (a cytochrome P450 [CYP]3A4 substrate) in Healthy Adult Participants.
- Trial name
- NCT05032950
- Testing
- Midazolam, PF-07321332/ritonavir + Midazolam, Ritonavir + Midazolam
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sars-CoV2, Symptomatic Condition
PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine…
- Conditions
- Sars-CoV2, Symptomatic Condition, Covid-19
- Trial name
- PRECISE (NCT04351191)
- Testing
- Hydroxychloroquine Sulfate Regular dose, Hydroxychloroquine Sulfate Loading Dose, Chloroquine
- Where
- 4 sites in Pakistan
- Volunteers
- 137 people
- Sponsor
- Government of Punjab, Specialized Healthcare and Medical Education Department
Coronavirus
The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19
COVID-19 is a new disease and therefore it is still not clear exactly how the virus affects the body and why people are affected so differently.
- Trial name
- NCT04453527
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Coronavirus Disease 2019 (COVID-19)
A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults
To evaluate the safety and tolerability of a single dose of 600 mg AZD7442 administered IV (intravenous) to Chinese adults (including those with stable medical conditions).
- Trial name
- NCT05184062
- Testing
- 600 mg AZD7442 IV
- Where
- 14 sites in China
- Volunteers
- 272 people
- Sponsor
- AstraZeneca
Virus Diseases
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases.
- Trial name
- COVIMAR (NCT04710199)
- Testing
- Maraviroc experimental group, Standard treatment
- Where
- 2 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Coronavirus Disease 2019 (COVID-19)
Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency
In this prospective observational study we aim to study the association of vitamin D deficiency with adverse clinical outcomes in patients infected with Coronavirus disease 2019
- Trial name
- COVIT-D (NCT04403932)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital San Carlos, Madrid
Coronavirus Disease 2019
Identify Coronavirus Disease by Chest X-ray
to identify the diagnostic accuracy of chest X-ray in diagnosis of Coronavirus disease19 .
- Trial name
- NCT05216471
- Testing
- chest X-ray
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Healthy Participants
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following…
- Trial name
- NCT05129475
- Testing
- PF-07321332/ritonavir, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
The purpose of this research study is to find out if CCP is safe and to determine the safest and most effective level of anti-viral antibody when given to people admitted to the hospital with confirmed COVID-19 infection.
- Trial name
- UNC CCP RCT (NCT04524507)
- Testing
- High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma (CCP2)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of North Carolina, Chapel Hill
Coronavirus Disease 2019 (COVID-19)
Collection of Anti-SARS-CoV-2 Immune Plasma
Background: The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 is a mild to moderate respiratory illness. But it can also be more severe and even lead to death.
- Trial name
- NIAID (NCT04344977)
- Where
- 3 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Malignant Solid Neoplasm, COVID-19 Infection
Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer
This study assesses the level of distress felt by cancer patients due to the coronavirus disease 2019 (COVID-19) pandemic. Researchers also want to learn if patients prefer to receive supportive care (palliative care) in person…
- Conditions
- Advanced Malignant Solid Neoplasm, COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05058339
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- M.D. Anderson Cancer Center
Covid19
COVID-19 Surveillance and Exposure Testing in School Communities
This is a prospective, observational study of COVID-19 surveillance and exposure testing in school communities. Participating school communities are providing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests to…
- Trial name
- NCT04831866
- Where
- 2 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Duke University